HiLung Inc. is pleased to announce that our CEO, Yuki Yamamoto, will present our latest research at the ISSCR 2026 Annual Meeting, taking place in Montréal, Canada, from July 8 to 11, 2026.
The presentation will highlight HiLung’s fully in vitro platform for inducing functional tissue-resident alveolar macrophages from human iPS cells, as well as its applications in respiratory disease modeling and lung toxicology.
As the demand continues to grow for human-relevant disease models and next-generation safety assessment platforms, HiLung remains committed to advancing iPSC-based lung biology, drug discovery, and translational science.